Taken together, our study provides compelling evidence that inhibition of ERp57 affects proliferation and apoptosis of cancer cells and that the development of specific inhibitors for ERp57 could help to improve the outcome of future cancer therapies. This evidence concerns the gene PDIA3 and cancer.